logo

Cellectar Biosciences Inc (CLRB)



Trade CLRB now with
  Date
  Headline
9/29/2016 8:34:14 AM Cellectar Biosciences Announces New Positive Data From Phase I Clinical Study Of CLR 131 In Multiple Myeloma
9/12/2016 8:35:28 AM Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head And Neck Cance
7/20/2016 8:30:35 AM Cellectar Biosciences Appoints Jarrod Longcor SVP Of Corporate Development And Operations
6/15/2016 8:33:05 AM Cellectar Announces Results Of In Vivo Study Demonstrating PDC Platform Delivery Of Paclitaxel
4/15/2016 8:37:33 AM Cellectar Biosciences Reports Pricing Of $7 Mln Public Offering
3/4/2016 4:19:48 PM Ellectar Biosciences Announces 1-for-10 Reverse Stock Split
1/5/2016 8:37:45 AM Cellectar Biosciences Repoorts Positive Data From Phase 1 Therapeutic Trial Of CLR 131 In Multiple Myeloma
12/16/2015 8:30:10 AM Cellectar Biosciences, Pierre Fabre Laboratories Announce Oncology Research Collaboration
12/9/2015 8:35:59 AM Cellectar Biosciences Plans To Provide Update On Phase 1 Multiple Myeloma Study
11/12/2015 4:58:37 PM Cellectar Biosciences Q3 Loss/share $0.25 Vs. Profit $0.06 Year Ago
10/1/2015 8:37:29 AM Cellectar Biosciences Awarded $2.3 Mln National Cancer Institute Fast-Track SBIR Grant To Advance PDC Delivery Platform
9/28/2015 8:35:08 AM Cellectar Biosciences Reports Pricing Of $3.3 Mln Financing
8/21/2015 8:38:09 AM Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate Platform For Targeted Delivery Of Chemotherapeutics
8/12/2015 4:34:27 PM Cellectar Biosciences Q2 Loss Per Share Of $0.30 Vs. $0.73 Last Year
6/16/2015 11:53:03 AM Cellectar Appoints Jim Caruso CEO